Shares of Viking Therapeutics have surged an impressive 34% over the last quarter, establishing the biotech firm as a standout performer. This momentum is fueled by the advancement of its obesity drug candidate, VK2735, and intensifying market speculation that the company could become a takeover target.
A Lucrative Market Attracts Major Players
The stock is benefiting significantly from heightened merger and acquisition interest in the lucrative obesity drug sector. A recent, fierce bidding war that concluded with Pfizer’s $10 billion acquisition of Metsera—a contest that involved Novo Nordisk—has placed Viking squarely in the spotlight as a potential next candidate. Analysts at Goldman Sachs project the U.S. obesity market could reach a staggering $100 billion by 2030. While Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy currently lead, numerous pharmaceutical giants are competing for a stake in the next generation of GLP-1 therapies.
Clinical Trials Exceeding Expectations
Viking reached a critical milestone in mid-November by completing patient enrollment for its Phase 3 trial, VANQUISH-1, ahead of schedule. The study successfully enrolled 4,650 participants, surpassing its original target of 4,500. This 78-week trial is evaluating a subcutaneous formulation of VK2735 in obese adults with weight-related comorbidities. This marks the second time this year the company has exceeded recruitment goals, signaling strong interest in the treatment.
Further bolstering optimism, recent Phase 2 results from the VENTURE study demonstrated compelling efficacy. A remarkable 78% of prediabetic patients treated with VK2735 achieved normal blood glucose levels, compared to just 29% in the placebo group. Significant improvements in diabetes and metabolism markers were observed after only 13 weeks of treatment.
Should investors sell immediately? Or is it worth buying Viking Therapeutics?
Financial Health and Valuation Metrics
Viking ended the third quarter with a robust cash position of $715 million, which management states is sufficient to fund its Phase 3 program. However, the company’s quarterly loss widened to $0.81 per share as research and development expenses surged from $22.8 million to $90 million.
The stock currently trades at a price-to-book multiple of 5.84, notably higher than the industry average of 3.60. Despite this premium valuation, analysts see considerable upside, with an average price target of $93. Canaccord Genuity is notably more bullish, having raised its target to $107 per share.
The Road Ahead: Catalysts on the Horizon
Looking forward, the ongoing Phase 3 VANQUISH-2 study represents another potential catalyst. This trial involves approximately 1,100 overweight or obese patients with Type 2 diabetes, with patient recruitment scheduled for completion in the first quarter of 2026. As clinical programs progress, Viking Therapeutics remains a closely watched name at the intersection of clinical promise and strategic acquisition potential.
Ad
Viking Therapeutics Stock: Buy or Sell?! New Viking Therapeutics Analysis from December 4 delivers the answer:
The latest Viking Therapeutics figures speak for themselves: Urgent action needed for Viking Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 4.
Viking Therapeutics: Buy or sell? Read more here...
